Эффективность препарата марибавир по данным клинических исследований

   Современная медицина испытывает высокую потребность в новых препаратах для профилактики и лечения цитомегаловирусной (ЦМВ) инфекции. В данном обзоре рассматривается марибавир — пероральный противовирусный препарат с селективной мультимодальной анти-ЦМВ -активностью для лечения взрослых и детей с посттрансплантационной ЦМВ-инфекцией, резистентной к традиционной анти-ЦМВ-терапии. Несмотря на множество клинических испытаний препарата марибавир, результаты его эффективности неоднозначны. Наряду с успешными исследованиями, результаты которых говорят о высокой эффективности обозреваемого препарата, имеются данные о статистически безуспешных исследованиях.

   Целью настоящего обзора является рассмотрение механизма действия препарата марибавир на цитомегаловирусную инфекцию, механизмов вирусной чувствительности и кросс-резистентности, а также обобщение результатов клинических исследованиях препарата.

1. Haidar G., Boeckh M., Singh N. Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J. Infect. Dis. 2020;221(1):S23–S31. DOI: 10.1093/infdis/jiz454

2. Teira P., Battiwalla M., Ramanathan M. et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–38. DOI: 10.1182/blood-2015-11-679639

3. Khawaja F., Batista M.V., El Haddad L., Chemaly R.F. Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management. Curr. Opin. Infect. Dis. 2019;32(6):565–574. DOI: 10.1097/QCO.0000000000000607

4. Mehta Steinke S.A., Alfares M., Valsamakis A. et al. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. Transpl. Infect. Dis. 2021;23(3):e13521. DOI: 10.1111/tid.13521

5. Biron K.K., Harvey R.J., Chamberlain S.C. et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 2002;46(8):2365–72. DOI: 10.1128/AAC.46.8.2365-2372.2002

6. Drew W.L., Miner R.C., Marousek G.I., Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J. Clin. Virol. 2006;37(2):124–7. DOI: 10.1016/j.jcv.2006.07.010

7. Avery R.K., Alain S., Alexander B.D. et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin. Infect. Dis. 2022;75(4):690–701. DOI: 10.1093/cid/ciab988

8. Chou S., Wechel L.C., Marousek G.I. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis. 2007;196(1):91–4. DOI: 10.1086/518514

9. Hamirally S., Kamil J.P., Ndassa-Colday Y.M. et al. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog. 2009;5(1):e1000275. DOI: 10.1371/journal.ppat.1000275

10. Chou S., Hakki M., Villano S. Eff ects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. Antiviral. Res. 2012;95(2):88–92. DOI: 10.1016/j.antiviral.2012.05.013

11. Chou S., Song K., Wu J. et al. Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection. J. Infect. Dis. 2022;226(4):576–584. DOI: 10.1093/infdis/jiaa462

12. Chou S., Wu J., Song K., Bo T. Novel UL97 drug resistance mutations identifi ed at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. Antiviral. Res. 2019;172:104616. DOI: 10.1016/j.antiviral.2019.104616

13. Chou S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob. Agents Chemother. 2009;53(1):81–5. DOI: 10.1128/AAC.01177-08

14. Chou S., Marousek G.I., Senters A.E. et al. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 2004;78(13):7124–30. DOI: 10.1128/JVI.78.13.7124-7130.2004

15. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 2008;18(4):233–46. DOI: 10.1002/rmv.574

16. Reitsma J.M., Savaryn J.P., Faust K. et al. Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest. Cell Host Microbe. 2011;9(2):103–14. DOI: 10.1016/j.chom.2011.01.006

17. Kamil J.P., Coen D.M. HATs on for drug resistance. Cell Host Microbe. 2011;9(2):85–7. DOI: 10.1016/j.chom.2011.02.001

18. Chou S., Marousek G.I. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J. Virol. 2008;82(1):246–53. DOI: 10.1128/JVI.01787-07

19. Chou S., Marousek G.I. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob. Agents Chemother. 2006;50(10):3470–2. DOI: 10.1128/AAC.00577-06

20. Selleseth D.W., Talarico C.L., Miller T. et al. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob. Agents Chemother. 2003;47(4):1468–71. DOI: 10.1128/AAC.47.4.1468-1471.2003

21. Evers D.L., Komazin G., Shin D. et al. Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. Antiviral. Res. 2002;56(1):61–72. DOI: 10.1016/s0166-3542(02)00094-3

22. Chou S., Ercolani R.J., Derakhchan K. Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. Antiviral. Res. 2018;157:128–133. DOI: 10.1016/j.antiviral.2018.07.013

23. Wang L.H., Peck R.W., Yin Y. et al. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodefi ciency virus-infected subjects. Antimicrob. Agents Chemother. 2003;47(4):1334–42. DOI: 10.1128/AAC.47.4.1334-1342.2003

24. Lalezari J.P., Aberg J.A., Wang L.H. et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodefi ciency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 2002;46(9):2969–76. DOI: 10.1128/AAC.46.9.2969-2976.2002

25. Canas S.M., Johnson J., Gelone S. et al. Bioavailability of maribavir whole tablet is unaff ected by crushing the tablet. Transplantation and Cellular Therapy. 2009;15(2):109. DOI: 10.1016/j.bbmt.2008.12.335

26. Song I., Ilic K., Sun K., Martin P. Clinical pharmacology of maribavir (SHP620): a comprehensive overview. Biol. Blood Marrow Transplant. 2019;25:S342. DOI: 10.1016/j.bbmt.2018.12.554

27. Ma J.D., Nafziger A.N., Villano S.A. et al. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob. Agents Chemother. 2006;50(4):1130–5. DOI: 10.1128/AAC.50.4.1130-1135.2006

28. Marty F.M., Boeckh M. Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed? Curr. Opin. Virol. 2011;1(6):555–62. DOI: 10.1016/j.coviro.2011.10.011

29. Williams S.L., Hartline C.B., Kushner N.L. et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 2003;47(7):2186–92. DOI: 10.1128/AAC.47.7.2186-2192.2003

30. Koszalka G.W., Johnson N.W., Good S.S. et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 2002;46(8):2373–80. DOI: 10.1128/AAC.46.8.2373-2380.2002

31. Swan S.K., Smith W.B., Marbury T.C. et al. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J. Clin. Pharmacol. 2007;47(2):209–17. DOI: 10.1177/0091270006296765

32. Maffini E., Giaccone L., Festuccia M. et al. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. Expert Rev. Hematol. 2016;9(6):585–96. DOI: 10.1080/17474086.2016.1174571

33. Pescovitz M.D., Bloom R., Pirsch J. et al. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. Am. J. Transplant. 2009;9(10):2324–30. DOI: 10.1111/j.1600-6143.2009.02768.x

34. Halpern-Cohen V., Blumberg E.A. New perspectives on antimicrobial agents: maribavir. Antimicrob. Agents Chemother. 2022;66(9):e0240521. DOI: 10.1128/aac.02405-21

35. Winston D.J., Young J.A., Pullarkat V. et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111(11):5403–10. DOI: 10.1182/blood-2007-11-121558

36. Marty F.M., Ljungman P., Papanicolaou G.A. et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect. Dis. 2011;11(4):284–92. DOI: 10.1016/S1473-3099(11)70024-X

37. Winston D.J., Saliba F., Blumberg E. et al. Effi cacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am. J. Transplant. 2012;12(11):3021–30. DOI: 10.1111/j.1600-6143.2012.04231.x

38. Maertens J., Cordonnier C., Jaksch P. et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N. Engl. J. Med. 2019;381(12):1136–1147. DOI: 10.1056/NEJMoa1714656

39. Alain S., Revest M., Veyer D. et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant. Proc. 2013;45(4):1603–7. DOI: 10.1016/j.transproceed.2013.01.082

40. Avery R.K., Marty F.M., Strasfeld L. et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl. Infect. Dis. 2010;12(6):489–96. DOI: 10.1111/j.1399-3062.2010.00550.x

41. Papanicolaou G.A., Silveira F.P., Langston A.A. et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin. Infect. Dis. 2019;68(8):1255–1264. DOI: 10.1093/cid/ciy706

42. ClinicalTrials.gov: USA. [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT05137717 (data access: 30. 05. 2023).

43. Kotton C.N., Kumar D., Caliendo A.M. et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900–931. DOI: 10.1097/TP.0000000000002191